biopharma-reporter7d
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
biopharma-reporter7d
Inhibikase to pause development of Parkinson’s drug
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...
biopharma-reporter9d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
biopharma-reporter9d
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
biopharma-reporter14d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...
biopharma-reporter14d
Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss
The Spanish contract development and manufacturing organization (CDMO) Viralgen and UK gene therapy developer Axovia Therapeutics announced yesterday that they have joined forces to boost the ...
biopharma-reporter14d
Bio developments
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...